
    
      Patients to be included:

        1. Elderly patients (>60 years of age) or other patients unfit for conventional intensive
           chemotherapy with newly diagnosed acute myelogenous leukemia (AML).

        2. Adult patients of any age (>18 years of age) with relapsed or resistant AML who cannot
           receive conventional therapy.

      Treatment:

      Valproic acid to be started on day 1 as continuous therapy until disease progression.

      ATRA administered from day 8 orally as 22.5 mg/m2 twice daily for 14 days, repeated every
      third month.

      Low-dose cytarabine 10 mg/m2 from day 14 and continued as daily injections for up to 10 days,
      repeated every third month.

      Supportive therapy is given according to the hospitals general guidelines.

      Followup: The first 2 days treatment in hospital, later regular out-patient treatment.
      Controls will include clinical examination, peripheral blood parameters (including serum
      valproic acid levels), bone marrow samples.
    
  